Breaking News Instant updates and real-time market news.

IART

Integra LifeSciences

$49.80

-0.29 (-0.58%)

, TFX

Teleflex

$295.36

-1.99 (-0.67%)

04:55
05/16/19
05/16
04:55
05/16/19
04:55

BofA/Merrill to hold a conference

2019 Healthcare Conference will be held in Las Vegas on May 13-16.

IART

Integra LifeSciences

$49.80

-0.29 (-0.58%)

TFX

Teleflex

$295.36

-1.99 (-0.67%)

BDX

Becton Dickinson

$225.47

2.69 (1.21%)

CTLT

Catalent

$44.71

0.715 (1.63%)

JAZZ

Jazz Pharmaceuticals

$138.21

1.93 (1.42%)

KALA

Kala Pharmaceuticals

$5.92

0.07 (1.20%)

HUM

Humana

$243.66

8.44 (3.59%)

SAGE

Sage Therapeutics

$166.76

0.63 (0.38%)

MRNA

Moderna

$22.97

-0.62 (-2.63%)

UHS

Universal Health

$121.91

-0.58 (-0.47%)

GILD

Gilead

$65.29

0.24 (0.37%)

SYK

Stryker

$185.70

1.47 (0.80%)

XENT

Intersect ENT

$26.49

0.38 (1.46%)

ALGT

Allegiant Travel

$144.53

-0.04 (-0.03%)

HOLX

Hologic

$44.88

-0.01 (-0.02%)

BLUE

Bluebird Bio

$124.71

-2.05 (-1.62%)

ANAB

AnaptysBio

$72.40

0.63 (0.88%)

PCRX

Pacira

$45.61

-0.99 (-2.12%)

MCK

McKesson

$126.30

0.73 (0.58%)

RHHBY

Roche

$0.00

(0.00%)

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 20

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 11

    Jun

  • 20

    Jun

  • 23

    Jun

  • 06

    Aug

  • 15

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

  • 13

    Nov

IART Integra LifeSciences
$49.80

-0.29 (-0.58%)

01/03/19
RHCO
01/03/19
INITIATION
Target $56
RHCO
Buy
Integra LifeSciences initiated with a Buy at SunTrust
SunTrust analyst Bruce Nudell initiated Integra LifeSciences with a Buy rating and a price target of $56, saying the "temporary" headwinds experienced by the company in Q3 and the subsequent pullback in its stock price present a "buying opportunity". The analyst cites the company's progress in integrating its "Codman acquisition, expanding its geographic footprint, augmenting and optimizing its distribution channels and introducing new products that should drive 5.5% organic growth over the 2018-22 timeframe."
04/25/19
OPCO
04/25/19
NO CHANGE
Target $65
OPCO
Outperform
Integra LifeSciences price target lowered to $65 from $70 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Integra LifeSciences to $65 from $70 following quarterly results on recent peer multiple contraction. The analyst reiterates an Outperform rating on the shares.
03/11/19
PIPR
03/11/19
NO CHANGE
Target $62
PIPR
Overweight
Integra warning letter 'not the end of the world,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says he spoke to Integra LifeSciences after the company disclosed a warning letter relating to its wound care manufacturing facility in Boston. The company emphasized that there were no safety issues associated with the products, O'Brien tells investors in a research note. The analyst does not expect the letter to impact revenue much, if at all. Management believes that it will be able to have the issue resolved within about six months, he adds. These FDA warnings letters happen, and is "not the end of the world" for Integra's wound care business, says O'Brien. He keeps an Overweight rating on Integra LifeSciences with a $62 price target.
02/21/19
02/21/19
NO CHANGE

Piper reiterates Overweight rating on Integra after Q4 earnings
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $62 price target on Integra LifeSciences after the company reported better-than-expected Q4 earnings, including Q4 sales of $383.3M which represented growth of ~4% and was on the higher end of the company's preannounced range of $378-383M. Additionally, Integra guided for FY19 adjusted earnings of $2.64-$2.72, ahead of Piper's previous estimate of $2.61.
TFX Teleflex
$295.36

-1.99 (-0.67%)

04/24/19
NEED
04/24/19
DOWNGRADE
NEED
Buy
Teleflex downgraded to Buy from Strong Buy at Needham
04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees Q1 revenue upside for Inogen, Teleflex, Align Technology
Piper Jaffray analyst Matt O'Brien says his deep dive into the MedTech companies exploring the direct-to-consumer sales channel came up "most compelling" for Inogen (INGN), Teleflex (TFX) and Align Technology (ALGN). Website traffic at these companies is at or near three-year highs and historical trends suggest a high likelihood of revenue upside in Q1, O'Brien tells investors in a research note. The analyst also found DexCom's (DXCM) website traffic to be at three-year highs.
04/24/19
NEED
04/24/19
DOWNGRADE
Target $325
NEED
Buy
Teleflex downgraded to Buy from Strong Buy at Needham
Needham analyst Mike Matson downgraded Teleflex to Buy while keeping his $325 price target , saying the company's organic growth may moderate in 2019 as revenue comps become "progressively more difficult" in each quarter. While he continues to expect Teleflex to top consensus, he does not see "enough EPS upside" that would "meaningfully" reduce its multiple.
03/22/19
UBSW
03/22/19
NO CHANGE
Target $350
UBSW
Buy
Teleflex price target raised to $350 from $325 at UBS
UBS analyst Matthew Taylor raised his price target on Teleflex to $350 and kept his Buy rating, saying its investor meeting discussions suggested that the management is confident in 2019 growth outlook of 6%-7%. The analyst cites the strength of the company's portfolio, acquisitions like NeoTract,Vascular Solutions, and Vidacare, as well as the impact of its eliminated "drags" associated with slower growth and margin business assets. Taylor believes that while the consensus models a 6.5% revenue growth this year, upside to that forecast is "very doable".
BDX Becton Dickinson
$225.47

2.69 (1.21%)

05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
WELS
05/13/19
NO CHANGE
Target $265
WELS
Outperform
Becton Dickinson price target lowered to $265 from $280 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Becton Dickinson to $265 from $280 after the company reported mixed Q2 results and maintained 2019 underlying sales growth guidance while lowering the EPS outlook. The analyst reiterates an Outperform rating on the shares.
05/13/19
LEHM
05/13/19
UPGRADE
Target $266
LEHM
Overweight
Barclays upgrades Becton Dickinson to Overweight following recent pullback
Barclays analyst Kristen Stewart upgraded Becton Dickinson to Overweight from Equal Weight with an unchanged price target of $266. The pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors, Stewart tells investors in a research note. The analyst believes the reaction to the FDA update is overdone and that the upcoming FDA Committee meeting on June 19-20 is likely to provide greater clarity and calm drug-coated balloons concerns.
05/13/19
LEHM
05/13/19
UPGRADE
Target $266
LEHM
Overweight
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Kristen Stewart upgraded Becton Dickinson to Overweight from Equal Weight with a $266 price target.
CTLT Catalent
$44.71

0.715 (1.63%)

04/16/19
UBSW
04/16/19
UPGRADE
Target $54
UBSW
Buy
Catalent upgraded to Buy from Neutral at UBS
UBS analyst Daniel Brennan upgraded Catalent to Buy and raised his price target to $54 from $43, saying the company's acquisition of Paragon "significantly increases the exposure to the rapidly growing biologic production market" which he sees as "arguably the most attractive sub segment within the broader life science tools sector today." The analyst models the deal to be accretive by over 200bps to Catalent's revenue and EBITDA in the long term and potentially higher in the near term, adding that his price target assumes EBITDA multiple of 14-times - a 2-turn premium to the stock's long-term average. Brennan further notes that his "recent diligence" suggests that the "bullishness about the gene therapy market is warranted."
04/16/19
MSCO
04/16/19
NO CHANGE
Target $50
MSCO
Overweight
Catalent price target raised to $50 after Paragon deal at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said Catalent's acquisition of Paragon Bioservices solidifies the company's position in the biologics marketplace and further improves its growth profile. He now model fiscal 2020 revenue of $2.9B and EBITDA of $732M, up from $2.7B and $668M, respectively. Goldwasser raised his price target on Catalent shares to $50 from $46 following the deal announcement and keeps an Overweight rating on the stock.
04/16/19
JEFF
04/16/19
NO CHANGE
Target $50
JEFF
Hold
Catalent price target raised to $50 from $44 at Jefferies
Jefferies analyst David Windley raised his price target for Catalent to $50 from $44 saying the acquisition of Paragon accelerates management's push into higher growth biologic/gene therapy areas. The analyst views the company's raised growth rate as achievable. His calculations indite Catalent can "easily" get to the 6%-8% revenue growth range, while earnings growth accelerates to low-to-mid teens. Windley keeps a Hold rating on the shares.
04/15/19
PIPR
04/15/19
NO CHANGE
PIPR
Catalent acquisition of Paragon 'a good deal,' says Piper Jaffray
Piper Jaffray analyst Sean Wieland reiterated an Overweight rating and $47 price target on Catalent after the company announced the acquisition of Paragon, which the analyst believes will be accretive to Catalent's growth and profitability in the long term, and gives the company's long-term organic revenue growth target a boost. Wieland called the Paragon acquisition a "strong strategic fit" and said the price, relative to a recent comp, is "a good deal."
JAZZ Jazz Pharmaceuticals
$138.21

1.93 (1.42%)

03/19/19
WELS
03/19/19
NO CHANGE
Target $162
WELS
Outperform
Wells Fargo boosts Jazz target to $162, sees 'several' 2019 catalysts
Wells Fargo analyst David Maris raised his 2019 earnings per share estimate for Jazz Pharmaceuticals to $14.58 from $13.81 and 2020 estimate to $16.59 from $16.35 to reflect the company's guidance and annual report. Maris also increased his price target for the shares to $162 from $154. The analyst sees "several catalysts" in 2019 for the stock, including Xyrem launch for pediatric indication in late Q1, JZP-258 topline results for Phase 3 study in narcolepsy in Spring 2019, and the Solriamfetol FDA action date of March 20. Further, investors are looking for a deal to diversify away from Xyrem, and at the end of 2018, Jazz had cash and investments of $825M as well as undrawn capacity on its revolver of $1.6B, Maris tells investors in a research note. He maintains an Outperform rating on the shares.
03/21/19
WELS
03/21/19
NO CHANGE
Target $154
WELS
Outperform
Jazz appoval expected but still 'nice win' for shares, says Wells Fargo
Wells Fargo analyst David Maris says FDA approval of solriamfetol for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, while largely expected by investors, is still a "nice win" for shares of Jazz Pharmaceuticals. The analyst estimates sales for solriamfetol of approximately $12M in 2019, ramping to $371M by 2023. Maris reiterates an Outperform rating on Jazz with a $154 price target. Additional potential catalysts for the stock include the Xyrem launch for pediatric indication in late Q1, JZP258 topline results for a Phase 3 study in narcolepsy in Spring 2019, and any update on the business development front, Maris tells investors in a research note. Jazz in midday trading is up 3%, or $3.45, to $137.02.
03/19/19
RHCO
03/19/19
INITIATION
Target $163
RHCO
Buy
Jazz Pharmaceuticals initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started Jazz Pharmaceuticals with a Buy rating and $163 price target. The analyst expects the company to deliver "continued strong" revenue and earnings growth over the next several years. Further, he believes the market may not fully appreciate the size and durability of Jazz's largest product Xyrem.
03/27/19
MZHO
03/27/19
NO CHANGE
Target $147
MZHO
Buy
Jazz Pharmaceuticals price target raised to $147 from $137 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Jazz Pharmaceuticals to $147 from $137 to reflect the recent approval of Sunosi and last night's positive data in the Phase III trial of JZP-258. However, both of these events were largely expected, Koffler tells investors in a research note. She reiterates a Neutral rating on Jazz Pharmaceuticals.
KALA Kala Pharmaceuticals
$5.92

0.07 (1.20%)

04/24/19
OPCO
04/24/19
INITIATION
Target $11
OPCO
Outperform
Kala Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated Kala Pharmaceuticals with an Outperform and $11 price target.
03/14/19
03/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/19
JEFF
03/14/19
INITIATION
Target $15
JEFF
Buy
Jefferies starts Kala Pharmaceuticals with Buy rating, $15 price target
Jefferies analyst Biren Amin initiated coverage of Kala Pharmaceuticals with a Buy rating and $15 price target. The company has reformulated loteprednol, an ocular steroid, with mucus-penetrating particles to provide superior penetration versus traditional steroid eye drops, Amin tells investors in a research note. It lead asset Inveltys is launching for use in post-operation surgeries and investors assume a slow launch for a product that could generate $150M in peak sales, the analyst adds. Further, he believes KPI-121 0.25% provides a "second and more meaningful catalyst" with Stride 3 pivotal data in dry eye at year-end 2019.
04/25/19
04/25/19
INITIATION
Target $11

Outperform
Oppenheimer initiates Kala with Outperform, sees attractive growth story
As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Kala Pharmaceuticals with an Outperform rating and $11 price target. With strong initial uptake of Inveltys, and KPI-121 regulatory catalyst in Q3, the analyst believes Kala Pharmaceuticals is well positioned for top line growth. His channel checks with ocular surgeons support Inveltys prescription growth over the next twelve months. Separately, he believes KPI-121 may address a significant unmet need in the nascent dry eye disease market.
HUM Humana
$243.66

8.44 (3.59%)

05/07/19
SBSH
05/07/19
NO CHANGE
SBSH
Citi sees low likelihood of Centene walking from WellCare deal
Amid reports suggesting shareholders could challenge Centene's (CNC) acquisition of WellCare (WCG), and Humana (HUM) possibly being interested in a takeover of Centene if the WellCare deal was dropped, Citi analyst Ralph Giacobbe says he's be surprised to see the deal unravel. Further, he'd be equally surprised to see Humana come over the top for Centene after its Medicaid win in Florida and recent commentary citing optimism in its organic direction. That said, there is a scarcity of Medicaid assets, and Humana has discussed its interest in dual and other higher acuity Medicaid populations, Giacobbe tells investors in a research note. Nonetheless, the analyst ultimately sees a low likelihood of Centene walking from the WellCare deal.
05/10/19
05/10/19
UPGRADE

Citi upgrades Anthem, Centene, UnitedHealth to Buy after 'extreme' selloff
Citi analyst Ralph Giacobbe upgraded Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) to Buy from Neutral while maintaining Buy ratings on Cigna (CI) and Humana (HUM). The magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone," Giacobbe tells investors in a research note. The analyst sees favorable risk/rewards in the sector and does not subscribe to the view of a continued "overhang" and "uncertainty." Instead, Giacobbe expects a share recovery as "more realistic views prevail and investors become more numb to the low-likelihood headlines and political rhetoric of single payor."
05/02/19
RHCO
05/02/19
NO CHANGE
Target $300
RHCO
Hold
Humana price target lowered to $300 from $345 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Humana to $300 to reflect lower industry multiples and also his reduced FY20 EPS outlook to $18.94 from $19.16. The analyst says that while the company's Q1 Medicare Advantage enrollment was better than expected, he sees the return of the health insurance industry fees, or HIF, slowing Humana's FY20 revenue growth below its 11%-15% long-term target.
05/02/19
FBCO
05/02/19
NO CHANGE
Target $315
FBCO
Outperform
Humana price target lowered to $315 from $352 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Humana to $315 from $352 following quarterly results given macro noise. The analyst reiterates an Outperform rating on the shares.
SAGE Sage Therapeutics
$166.76

0.63 (0.38%)

03/20/19
PIPR
03/20/19
NO CHANGE
Target $206
PIPR
Overweight
Sage Therapeutics approval in-line with expectations, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says FDA approval of Sage Therapeutics' Zulresso for postpartum depression, product labeling, and gross pricing of $34,000 are "entirely in-line with expectations." The analyst continues to believe the opportunity of a 60-hour intravenous infusion with restricted use is modest at $300M in peak sales. However, the commercial footprint Sage can establish with Zulresso should position the company well for maximal success with SAGE-217 in the postpartum depression setting, Brill tells investors in a research note. She reiterates an Overweight rating on the shares with a $206 price target.
04/25/19
04/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Frontdoor (FTDR) initiated with an Outperform at Raymond James. 2. Sage Therapeutics (SAGE) initiated with a Buy at Jefferies. 3. Eyenovia (EYEN) initiated with an Outperform at Oppenheimer. 4. DXP Enterprises (DXPE) initiated with a Hold at Jefferies. 5. Replimune Group (REPL) initiated with an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/19
HCWC
03/20/19
NO CHANGE
Target $254
HCWC
Buy
Ligand receives royalty on sales of Zulresso, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis points out that Ligand Pharmaceuticals (LGND) is entitled to a 3% royalty on the sales of Sage Therapeutics' (SAGE) Zulresso, which just received FDA approval. The approval also provides Ligand with a $3M milestone payment, Pantginis tells investors in a research note. The analyst thinks Zulresso "should maintain a comfortable niche" and he reiterates a Buy rating on Ligand with a $254 price target.
04/25/19
JEFF
04/25/19
INITIATION
Target $195
JEFF
Buy
Sage Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Andrew Tsai started Sage Therapeutics with a Buy rating and $195 price target. The analyst views Sage as "one of the cleaner, de-risked growth stories currently in biotech." The company is reshaping the depression-treatment paradigm, particularly given Zulresso and next-gen oral SAGE-217, Tsai tells investors in a research note. His doctor checks suggest SAGE-217's sales opportunity could be $4B-$6B, which he notes is likely above consensus.
MRNA Moderna
$22.97

-0.62 (-2.63%)

02/04/19
PIPR
02/04/19
NO CHANGE
Target $24
PIPR
Overweight
Piper a buyer of Moderna ahead of Phase 1 mRNA-1944 data
Piper Jaffray analyst Edward Tenthoff is a buyer of Moderna ahead of the Phase I data on mRNA-1944 chikungunya virus antibody in the first half of 2019. While the analyst ascribes no value for mRNA-1944 itself, he believes these data will have important read-through to Moderna's emerging Orphan Disease pipeline. mRNA-1944 is Moderna's first systemic secreted mRNA therapeutic and will validate mRNA-3704 for methylmalonic acidemia, mRNA-3927 for propionic acidemi, mRNA-3283 for phenylketonuria, mRNA-3630 for Fabry's disease and several as yet undisclosed orphan disease programs, Tenthoff tells investors in a research note. The analyst keeps an Overweight rating on Moderna with a $24 price target.
05/08/19
PIPR
05/08/19
NO CHANGE
Target $30
PIPR
Overweight
Moderna price target raised to $30 from $24 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target on shares of Moderna to $30 from $24 as he made pipeline adjustments following the company's annual Science Day. The analyst, who said he is "most excited by rapid progress and expansion of Moderna's orphan disease pipeline," noted that he sees multiple blockbuster opportunities for the company. Tenthoff keeps an Overweight rating on Moderna shares.
04/05/19
CHDN
04/05/19
INITIATION
Target $40
CHDN
Buy
Moderna initiated with a Buy at Chardan
Chardan analyst Gbola Amusa initiated Moderna (MRNA) with a Buy and $40 price target telling investors the company's therapeutics have potential utility across a spectrum of diseases given they can direct cells to produce intracellular, membrane, or secreted proteins. After demonstrating preclinical and clinical proof-of-concept in a number indications, Moderna has attracted the attention of big biopharma and has ongoing validating and de-risking collaborations with Merck & Co (MRK) and AstraZeneca (AZN).
02/05/19
PIPR
02/05/19
NO CHANGE
Target $24
PIPR
Overweight
Piper says Moderna mRNA-1944 data has important read-through to rest of pipeline
After Moderna announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944, Piper Jaffray analyst Edward Tenthoff said he sees an important read-through from this data, expected in the first half of 2019, to the rest of Moderna's orphan disease pipeline. The analyst, who thinks mRNA technology is ideally suited to address short-comings of Enzyme Replacement Therapy, keeps an Overweight rating and $24 price target on Moderna shares.
UHS Universal Health
$121.91

-0.58 (-0.47%)

04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
03/05/19
BMOC
03/05/19
NO CHANGE
Target $146
BMOC
Market Perform
Universal Health price target raised to $146 from $130 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on Universal Health to $146, citing its above-consensus outlook for 2019 announced last week. The analyst states that while the company remains "reliant on continued acute-care strength", the forecast has given him a better "view of expectations now that management has backed away from promises of near-term improvement in the behavioral side, which should strengthen its credibility." Borsch is keeping his Market Perform rating on Universal Health however, noting that its current valuation of enterprise value to EBITDA at 9.1-times is "fair" and implies only modest stock price upside.
03/04/19
03/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) downgraded to Underweight from Equal Weight at Barclays with analyst Matthew McClintock saying he believes there is "limited, if any," visibility into a potential inflection point towards improving traffic trends. 2. Hawaiian Holdings (HA) downgraded to Sell from Hold at Deutsche Bank with analyst Michael Linenberg citing increased competition given Southwest Airlines' (LUV) plans for inter-island flying. 3. Enbridge (ENB) downgraded to In Line from Outperform at Evercore ISI and to Sector Perform from Outperform at Scotiabank and National Bank. 4. SunTrust (STI) downgraded to Neutral from Buy at UBS with analyst Saul Martinez saying his Buy thesis no longer holds due to the proposed merger with BB&T (BBT). 5. Universal Health (UHS) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying while he does not have a "new active negative thesis" on the shares, he finds the stock "relatively fairly valued with limited catalysts." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/29/19
BMOC
04/29/19
NO CHANGE
Target $138
BMOC
Market Perform
Universal Health price target lowered to $138 from $146 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Universal Health to $138 and kept his Market Perform rating after its Q1 earnings miss, saying the results now imply reduced probability for the company to be able to achieve the high end of its FY19 EBITDA target range. The analyst notes that while wage pressures have continued in the quarter, Q1 underperformance was also driven by "lower-acuity volume mix on the acute-care side of the business that weakened the impact from strong volumes."
GILD Gilead
$65.29

0.24 (0.37%)

04/29/19
PIPR
04/29/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead the 'undisputed leader' in cell therapy, says Piper Jaffray
After conducting nearly 30 hours' worth of interviews with C-level management at numerous companies, Piper Jaffray analyst Tyler Van Buren calls Gilead Sciences the "undisputed leader" of the cell therapy space. The majority of the successes and learnings from the current generation of CAR-T products is attributable to Gilead/Kite's efforts, Van Buren tells investors in a research note. Further, he expect the company's ongoing studies and collaborations to "meaningfully improve" cell product characteristics and manufacturing conditions and ultimately result in better patient outcomes. The cell therapy space is still in its infancy and there is an" enormous opportunity ahead,' says the analyst. He keeps a Neutral rating on Gilead with a $75 price target.
05/03/19
WELS
05/03/19
UPGRADE
Target $120
WELS
Outperform
Intercept upgraded to Outperform following survey of doctors at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Intercept to Outperform from Market Perform, stating that his recent survey of NASH prescribing doctors following the REGENERATE study update suggests a higher expected adoption rate of obeticholic acid and a more positive view of its efficacy. He also said he views the shares as oversold with Intercept down 12.5% year-to-date. Birchenough, who also cited recent NASH study failures of liver disease leader Gilead (GILD), raised his price target on Intercept shares to $120 from $104.
05/10/19
RILY
05/10/19
NO CHANGE
Target $158
RILY
Buy
Intercept added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani earlier today added Intercept Pharmaceuticals (ICPT) to his firm's Alpha Generator list. The analyst sees "strong" strong fundamentals over next year and a high likelihood of FDA approval in mid-2020. Mamtani lowered his price target for Intercept to $158 from $169 and keeps a Buy rating on the shares. His new target reflects the company's recent capital raise, the removal of removing Gilead (GILD) as near-term competitor with selonsertib's recent failure, and the push out of a European launch from the second half of 2020 to Q1 of 2021.
05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
SYK Stryker
$185.70

1.47 (0.80%)

04/24/19
CANT
04/24/19
NO CHANGE
Target $190
CANT
Neutral
Stryker price target raised to $190 from $175 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Stryker to $190 from $175 saying the company's momentum continues following its Q1 results. The analyst, however, believes expectations remain high and keeps a Neutral rating on the shares.
04/24/19
LEHM
04/24/19
NO CHANGE
Target $211
LEHM
Equal Weight
Stryker earnings pullback a buying opportunity, says Barclays
Barclays analyst Kristen Stewart recommends using the post-earnings selloff in shares of Stryker as a buying opportunity. The market likely wanted a higher quality earrings beat, Stewart tells investors in a research note. The analyst, however, says her view on the company is unchanged. She continues to view Stryker as "capable of delivering above-peer growth thus worthy of a premium PE multiple." Stewart keeps an Overweight rating on the shares with a $211 price target.
04/24/19
OPCO
04/24/19
NO CHANGE
Target $192
OPCO
Outperform
Stryker price target raised to $192 from $183 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Stryker to $192 from $183 following quarterly results. The analyst reiterates an Outperform rating on the shares.
04/24/19
PIPR
04/24/19
NO CHANGE
Target $205
PIPR
Overweight
Stryker's 'broad-based momentum' continues, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Stryker reported a "clean" Q1 with beats on both the top- and bottom-lines. The Mako story continues with 35 global placements, O'Brien tells investors in a research note. Stryker's "broad-based momentum" continues, and it remains in the upper-quartile of large cap medtech growth, adds the analyst. He reiterates an Overweight rating on the stock with a $205 price target.
XENT Intersect ENT
$26.49

0.38 (1.46%)

05/07/19
05/07/19
DOWNGRADE
Target $29

Market Perform
Intersect ENT downgraded to Market Perform on SINUVA trajectory at SVB Leerink
As previously reported, SVB Leerink analyst Richard Newitter downgraded Intersect ENT to Market Perform from Outperform on a slower projected rev growth trajectory for both PROPEL and SINUVA. The issue continues to be reimbursement frictions that will now involve an even higher degree of sales organization's time/resources devoted to SINUVA versus that which management previously thought it had addressed with additional hiring during the second half of 2018, he notes. Newitter also lowered his price target on the shares to $29 from $41.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $35
PIPR
Overweight
Intersect ENT should be bought on any guidance selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends buying shares of Intersect ENT on any weakness following the company's weaker than expected 2019 guidance. The analyst expects the stock to sell off today but thinks Intersect ENT will be a "beat-and-raise story throughout the year." He views the outlook as conservative and keeps an Overweight rating on Intersect ENT with a $35 price target.
05/07/19
NORL
05/07/19
DOWNGRADE
Target $20
NORL
Underperform
Intersect ENT downgraded to Underperform from Market Perform at Northland
Northland analyst Suraj Kalia downgraded Intersect ENT to Underperform from Market Perform after the company cut its FY19 sales guidance and announced an "abrupt CEO change," which he tells investors "telegraphs implicit weakness in the outlook." The analyst, who said he has always had concerns that expectations on new product launches were overtly enthusiastic, cut his price target on Intersect ENT shares to $20 from $28.
05/07/19
LEER
05/07/19
DOWNGRADE
LEER
Market Perform
Intersect ENT downgraded to Market Perform from Outperform at SVB Leerink
ALGT Allegiant Travel
$144.53

-0.04 (-0.03%)

03/26/19
03/26/19
UPGRADE
Target $149

Outperform
Allegiant Travel upgraded to Outperform at Macquarie on strong leisure fares
As previously reported, Macquarie analyst Susan Donofrio upgraded Allegiant Travel to Outperform from Neutral and kept her $149 price target following her meetings with its management last week. The analyst notes that while the investment "story remains sloppy", the airline's "leisure fares" remain strong. Donofrio also notes that Allegiant Travel is relatively insulated from significant competition and its stock trades at a "quite compelling" valuation.
03/26/19
MACQ
03/26/19
UPGRADE
MACQ
Outperform
Allegiant Travel upgraded to Outperform from Neutral at Macquarie
04/26/19
IMPC
04/26/19
NO CHANGE
Target $180
IMPC
Outperform
Allegiant Travel price target raised to $180 from $162 at Imperial Capital
Imperial Capital analyst Michael Derchin raised his price target for Allegiant Travel Company to $180 from $162 following the company's Q1 results and keeps an Outperform rating on the name. The shares present an attractive opportunity, due to the Allegiant's "strong" fiscal 2019 core earnings outlook, "top-tier" margins, potential upside from revenue and cost initiatives, and its Sunseeker resort project, which is expected to open in 2020, Derchin tells investors in a research note.
03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HOLX Hologic
$44.88

-0.01 (-0.02%)

04/24/19
PIPR
04/24/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic checks suggest worsening Cynosure trends, says Piper Jaffray
Piper Jaffray analyst William Quirk says his eBay (EBAY) channel checks suggest Hologic's (HOLX) positive trends in his earlier research have reversed with more used Cynosure lasers hitting third party websites and prices trending down. While Cynosure represents just ~10% of Hologic's total revenue, it carries a "heavy psychological burden on the share price," Quirk tells investors in a research note. He maintains an Overweight rating on Hologic with a $49 price target, but recognizes the company's March quarter results may bring a better entry point if his checks prove accurate.
01/02/19
01/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
COWN
01/04/19
DOWNGRADE
COWN
Market Perform
Hologic downgraded to Market Perform from Outperform at Cowen
01/31/19
PIPR
01/31/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic price target raised to $49 from $45 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Hologic to $49 after the company reported fiscal Q1 results in-line with its preannouncement and raised guidance for fiscal 2019. The analyst continues to believe "core Hologic is moving in the right direction" and and he keeps an Overweight rating on the shares. He views the quarter as positive for the company and believes the guidance is reasonable.
BLUE Bluebird Bio
$124.71

-2.05 (-1.62%)

05/13/19
PIPR
05/13/19
NO CHANGE
PIPR
Piper 'incrementally more bullish' on GlycoMimetics, Global Blood
After speaking to a practicing hematologist and emergency medicine doctor at a leading medical institution, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT). The former has pivotal Phase 3 data with rivipansel expected in July and the latter is in the process of submitting a new drug application for voxelotor via the accelerated approval pathway, Brill tells investors in a research note. Further, the analyst says feedback from the expert reaffirmed her neutral outlook for Bluebird Bio's (BLUE) LentiGlobin. The hematologist expects rivipansel to be successful in the Phase 3 trial and anticipates use for most acute sickle cell disease crises requiring provider intervention, according to Brill. Further, she was surprised to hear how enthusiastic the expert was about voxelotor.
05/15/19
WEDB
05/15/19
DOWNGRADE
WEDB
Neutral
Bluebird Bio downgraded to Neutral from Outperform at Wedbush
03/05/19
03/05/19
DOWNGRADE
Target $145

Market Perform
Bluebird Bio downgraded to Market Perform on valuation at SVB Leerink
As previously reported, SVB Leerink analyst Mani Foroohar downgraded Bluebird Bio to Market Perform from Outperform, with a $145 price target. While the analyst remains optimistic on the company's ability to secure approval for BCMA, Lenti-D, and LentiGlobin programs, he believes the current valuation reflects these attractive fundamentals in line with his high probability of success assumptions.
05/15/19
05/15/19
DOWNGRADE
Target $131

Neutral
Bluebird Bio downgraded to Neutral at Wedbush on ZYNTEGLO launch risks
As previously reported, Wedbush analyst David Nierengarten downgraded Bluebird Bio to Neutral from Outperform after attending the company's Analyst Day, as he sees risks to the ZYNTEGLO launch that could overshadow its broad pipeline. Specifically, the analyst now expects installment, performance-based pricing of $320,000/year, in-line with annual treatment costs, for 5 years, or $1.6M total, with a 15% discount on the total potential price as some patients will not fully respond/meet the performance requirements. With installment pricing, Nierengarten incorporates additional financing in his model as it creates an "air gap" for cash flow that the company will have to fill before it becomes cash flow positive. The analyst also lowered his price target on the shares to $131 fr0m $166.
ANAB AnaptysBio
$72.40

0.63 (0.88%)

04/03/19
STFL
04/03/19
NO CHANGE
Target $124
STFL
Buy
AnaptysBio could have 45% upside in best-case for ANB019, says Stifel
Stifel analyst Derek Archila said that after his recent work on the subject, he cannot confidently conclude at this point whether or not AnaptysBio's ANB019 will be superior to spesolimab, Boehringer Ingelheim's first-mover in the class of IL-36 receptor antagonists. However, his work has made him more optimistic on the chances of ANB019 proving efficacious in its Phase 2 studies for generalized pustular psoriasis and palmoplantar pustulosis. In a best-case scenario where differentiating data sets ANB019 apart from spesolimab, the stock could have 45% in upside from current levels, added Archila, who keeps a Buy rating and $124 price target on AnaptysBio shares.
03/12/19
JPMS
03/12/19
NO CHANGE
JPMS
Overweight
AnaptysBio jumps after JPMorgan surveys doctors on asthma data
Shares of AnaptysBio (ANAB) are higher after JPMorgan analyst Anupam Rama asked 60 U.S. physicians about the company's Phase 2a eosinophilic asthma data for etokimab. While acknowledging the data for etokimab are early stage, Rama told investors earlier in a research note that he is "broadly encouraged" by the enthusiasm of the surveyed physicians. Regeneron's (REGN) cautious commentary on monotherapy activity of its IL-33 antibody, REGN3500, has emerged as an overhang on AnaptysBio's etokimab asthma program, but anecdotal feedback in the survey suggests IL-33 inhibition is viewed as an "interesting mechanism," Rama wrote. He sees a "number of potential value creating catalysts" for AnaptysBio shares in mid-2019, including Phase 2b data of etokimab in atopic dermatitis, Phase 2 data of etokimab in chronic rhinosinusitis with nasal polyps, and Phase 2 data from ANB019 in generalized pustular psoriasis. The analyst keeps an Overweight rating on AnaptysBio. The stock in late morning trading is up 9%, or $6.05, to $71.99 in late morning trading.
02/22/19
GUGG
02/22/19
INITIATION
Target $135
GUGG
Buy
AnaptysBio initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated AnaptysBio with a Buy rating and $135 price target, calling its lead asset, etokimab, a "a pipeline-in-a-product with blockbuster potential" given its potential for broad applicability across multiple atopic diseases.
01/18/19
RHCO
01/18/19
NO CHANGE
Target $125
RHCO
Buy
AnaptysBio price target lowered to $125 from $156 at SunTrust
SunTrust analyst Joon Lee lowered his price target on AnaptysBio to $125, citing increasing competition for its product. The analyst keeps his Buy rating however and expects its stock to show "significant upside from current levels in 2019" ahead of the four major data readouts to follow "already promising" phase 2 proof of concept data in atopic dermatitis and asthma. Lee is overall positive on AnaptysBio's "proprietary antibody generation platform that is able to mimic natural in vivo process of antibody diversity generation in an in vitro system".
PCRX Pacira
$45.61

-0.99 (-2.12%)

03/08/19
STFL
03/08/19
NO CHANGE
Target $33
STFL
Sell
Pacira price target lowered to $33 from $41 at Stifel
Stifel analyst Derek Archila lowered his price target on Pacira (PCRX) shares to $33 and reiterated a Sell rating on the stock, stating that the company's 22% year-over-year growth guidance for Exparel "is no lay-up" and he sees meaningful competitive pressure coming from Heron Therapeutics' (HRTX) HTX-011 and its expected positive news flow ahead of launch. While MyoScience's Iovera seems like it will fit very well within Pacira's current sales infrastructure, the acquisition of MyoScience "was certainly not the deal investors were looking for," added Archila.
05/06/19
MZHO
05/06/19
UPGRADE
Target $38
MZHO
Neutral
Pacira upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Pacira Biosciences (PCRX) to Neutral from Underperform and raised her price target for the shares to $38 from $29. The analyst says her sell thesis on the shares is longer valid due to an unexpected delay at competitor Heron Therapeutics (HRTX) and Pacira's stronger guidance on recently acquired iovera. However, she still remains concerned about the longer-term outlook for the company.
05/02/19
STFL
05/02/19
UPGRADE
Target $45
STFL
Hold
Stifel upgrades Pacira to Hold after Heron competition delayed
As previously reported, Stifel analyst Derek Archila upgraded Pacira (PCRX) to Hold from Sell after Heron Therapeutics (HRTX) announced yesterday that it received a Complete Response Letter from the FDA for its New Drug Application for HTX-011 for the management of postoperative pain. Archila now forecasts HTX-011's approval and launch in 2020 and thinks Pacira's Exparel will likely remain the only local, non-opioid, long-acting analgesic on the market through the remainder of 2019. He also believes a recent price increase and a favorable reimbursement scheme in the ASC setting should set the company up to achieve its 2019 Exparel guidance. However, Archila said key points from his Sell thesis still worry him long-term as he thinks other more competitive offerings, from Heron and others, will eventually come to market. Given his increased Exparel forecast and the incorporation of the recent acquisition of Iovera, Archila raised his price target on Pacira shares to $45 from $33.
05/02/19
STFL
05/02/19
UPGRADE
STFL
Hold
Pacira upgraded to Hold from Sell at Stifel
MCK McKesson
$126.30

0.73 (0.58%)

04/02/19
WOLF
04/02/19
INITIATION
Target $127
WOLF
Outperform
McKesson initiated with an Outperform at Wolfe Research
Wolfe Research initiated McKesson with an Outperform and $127 price target citing compelling cash flow yields.
04/03/19
MSCO
04/03/19
NO CHANGE
MSCO
Morgan Stanley says Walgreens' reimbursement pressure points to distributor risk
Morgan Stanley analyst Ricky Goldwasser said the guidance cut made by Walgreens Boots Alliance (WBA) is due to the same "perfect storm of industry headwinds" addressed by CVS Health (CVS) earlier in the year, including increased reimbursement pressure, lower generic deflation, lower brand inflation and declining comparable sales in the front-end of the store. Though Walgreens management suggested reimbursement headwinds should normalize in fiscal 2020, Goldwasser said he could see more downside from continued reimbursement headwinds and structural changes if new rebate rule comes into play. He also views pharmacy reimbursement pressure as a leading indicator suggesting risk to distributors' sell side margins and earnings, including for AmerisourceBergen (ABC), which Goldwasser notes is part of the WBAD purchasing consortium. Other drug distributors include McKesson (MCK) and Cardinal Health (CAH).
01/17/19
UBSW
01/17/19
INITIATION
Target $134
UBSW
Neutral
McKesson initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started McKesson with a Neutral rating and $134 price target.
03/04/19
BARD
03/04/19
NO CHANGE
BARD
Baird investigation finds Ohio, like many buyers, paying too much for drugs
In a research note titled "Major Confusion: Does This Pass Your Sniff Test?," Baird analyst Eric Coldwell details the interplay between Cardinal Health's (CAH) generic marketing company Major Pharmaceuticals and CVS Health (CVS) in Ohio. In Major's catalog is Omeprazole, a generic version of Prilosec, which is available without a subscription. CVS Caremark, which had majority share of pharmacy benefit management services in Ohio, didn't use Maximum Allowable Cost for the product, which led to the state of Ohio paying $6.74 per tablet, or 19 times the amount somebody without a subscription can buy it, Coldwell tells investors in a research note, citing his own investigation. Meanwhile, over the course of five quarters in Ohio, Major's volume market share went from less than 2% to nearly 60% while dollar market share went from 12% to 95%, adds the analyst. He asks, "How does this happen?" The state of Ohio, "like so many other buyers, feels like it is paying too much for drugs," concludes Coldwell.
RHHBY Roche
$0.00

(0.00%)

04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Wells says Ionis weakness on Roche Huntington's update a buying opportunity

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.